Prostate Cancer, Hereditary, 4 disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

HPC4 MCID: PRS135 MIFTS: 22	Prostate Cancer, Hereditary, 4 (HPC4) Categories: Cancer diseases, Genetic diseases, Rare diseases, Reproductive diseases
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Prostate Cancer, Hereditary, 4

MalaCards integrated aliases for Prostate Cancer, Hereditary, 4:

Name: Prostate Cancer, Hereditary, 4 ⁵⁶ ¹³ ⁷¹

Prostate Cancer, Hereditary, on Chromosome 7 ⁵⁶

Prostate Cancer, Susceptibility to, 4 ⁵⁶

Prostate Cancer 4 ⁵⁶

Hpc4 ⁵⁶

Classifications:

MalaCards categories:
Global: Cancer diseases Genetic diseases Rare diseases
Anatomical: Reproductive diseases

See all MalaCards categories (disease lists)

External Ids:

OMIM ⁵⁶ 608658

MedGen ⁴¹ C1837593

UMLS ⁷¹ C1837593

Sources

Summaries for Prostate Cancer, Hereditary, 4

MalaCards based summary : Prostate Cancer, Hereditary, 4, also known as prostate cancer, hereditary, on chromosome 7, is related to prostate cancer. An important gene associated with Prostate Cancer, Hereditary, 4 is HPC4 (Prostate Cancer, Hereditary, 4). The drugs 4-Aminopyridine and Potassium Channel Blockers have been mentioned in the context of this disorder. Affiliated tissues include prostate, t cells and lung.

Wikipedia : ⁷⁴ Prostate cancer, hereditary, 4 is a protein that in humans is encoded by the HPC4... more...

More information from OMIM: 608658

Sources

Related Diseases for Prostate Cancer, Hereditary, 4

Diseases in the Prostate Cancer family:

Prostate Cancer, Hereditary, 1	Prostate Cancer, Hereditary, 8
Prostate Cancer, Hereditary, 3	Prostate Cancer, Hereditary, 4
Prostate Cancer, Hereditary, 5	Prostate Cancer, Hereditary, 6
Prostate Cancer, Hereditary, 7	Prostate Cancer, Hereditary, 9
Prostate Cancer, Hereditary, 10	Prostate Cancer, Hereditary, 12
Prostate Cancer, Hereditary, 13	Prostate Cancer, Hereditary, 11
Prostate Cancer, Hereditary, 14	Prostate Cancer, Hereditary, 15
Prostate Cancer, Hereditary, 2	Prostate Carcinoma in Situ

Diseases related to Prostate Cancer, Hereditary, 4 via text searches within MalaCards or GeneCards Suite gene sharing:

#	Related Disease	Score	Top Affiliating Genes
1	prostate cancer	11.5

Sources

Symptoms & Phenotypes for Prostate Cancer, Hereditary, 4

Clinical features from OMIM:

608658

Sources

Drugs & Therapeutics for Prostate Cancer, Hereditary, 4

Drugs for Prostate Cancer, Hereditary, 4 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 8)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

4-Aminopyridine

Approved

Phase 4

504-24-5

1727

Synonyms:

.gamma.-Aminopyridine

[J.Pharmacol.Exp.Ther. 275:864 (1995)]

275875_ALDRICH

36687_FLUKA

36687_RIEDEL

4 Aminopyridine

4 Aminopyridine Sustained Release

4 AP

4-aminopyridine

4-Aminopyridine

4-Aminopyridine 10

4-Aminopyridine Sustained Release

4-AP

4-Pyridinamine

4-Pyridylamine

504-24-5

5-22-09-00106 (Beilstein Handbook Reference)

A 0152

A0414

A78403_ALDRICH

AB1004971

AC1L1C3R

AC1Q52BM

AC-907/25014071

AI3-52547

AKOS000119896

Amaya

Amino-4 pyridine

Amino-4-Pyridine

Ampydin

Ampyra

Avitrol

Avitrol 200

BB_SC-6974

Bio1_000353

Bio1_000842

Bio1_001331

Bio2_000282

Bio2_000762

BRN 0105782

BSPBio_001562

C13728

C5H6N2

Caswell No. 038

CHEBI:34385

CHEMBL284348

CID1727

Compound 1861

D015761

D04127

Dalfampridine

DivK1c_000572

EINECS 207-987-9

EL-970

EPA Pesticide Chemical Code 069201

EU-0100032

Fampridina

Fampridine

Fampridine (USAN/INN)

Fampridine [USAN:INN]

Fampridine SR

Fampridine-PR

Fampridine-SR

Fampridinum

FT-0083754

gamma-Aminopyridine

HC150041

HMS1361O04

HMS1791O04

HMS1921H15

HMS1989O04

HMS2092F05

HMS501M14

HSDB 6037

IDI1_000572

IDI1_034032

InChI=1/C5H6N2/c6-5-1-3-7-4-2-5/h1-4H,(H2,6,7

KBio1_000572

KBio2_000282

KBio2_000635

KBio2_002850

KBio2_003203

KBio2_005418

KBio2_005771

KBio3_000563

KBio3_000564

KBio3_001888

KBioGR_000282

KBioGR_001505

KBioSS_000282

KBioSS_000635

Lopac0_000032

Lopac-A-0152

LS-130202

Mi-W-3

MLS000069400

MolPort-000-146-022

NCGC00015009-01

NCGC00015009-03

NCGC00015009-12

NCGC00024890-01

NCGC00024890-02

NCGC00024890-03

NCGC00024890-04

NCGC00024890-05

NCGC00024890-06

NCGC00024890-07

NCGC00024890-08

NCGC00024890-09

NCGC00024890-10

nchem.892-comp4

Neurelan

Neurelan (TN)

NINDS_000572

NSC 15041

NSC15041

p-Aminopyridine

p-Aminopyridine [UN2671] [Poison]

Philips 1861

Phillips 1861

Pimadin (free base)

Prc 1237

Pymadin

Pymadine

pyridin-4-amine

pyridin-4-ylamine

PYRIDINE,4-AMINO

RCRA waste no. P008

SDCCGMLS-0066228.P001

SMR000058211

SPBio_001486

Spectrum_000155

SPECTRUM1501130

Spectrum2_001413

Spectrum3_000914

Spectrum4_001013

Spectrum5_001501

STK298717

Sustained Release, 4-Aminopyridine

TL8003344

Tocris-0940

UNII-BH3B64OKL9

UPCMLD-DP125

UPCMLD-DP125:001

VMI 103

VMI 10-3

VMI103

VMI-103

VMI-10-3

WLN: T6NJ DZ

γ-Aminopyridine

Potassium Channel Blockers

Phase 4

Choline

Approved, Nutraceutical

Phase 3

62-49-7

305

Synonyms:

(2-Hydroxyethyl)trimethyl ammonium

(2-Hydroxyethyl)trimethylammonium

(beta-Hydroxyethyl)trimethylammonium

2-Hydroxy-N,N,N-trimethylethanaminium

2-Hydroxy-N,N,N-trimethyl-ethanaminium

Bilineurine

Biocolina

Biocoline

Bitartrate, choline

Bursine

Chloride, choline

Choline bitartrate

Choline cation

Choline chloride

Choline citrate

Choline hydroxide

Choline ion

CHOLINE ion

Choline O sulfate

Choline O-sulfate

Cholinum

Citrate, choline

Fagine

Hepacholine

Hormocline

Hydroxide, choline

Lipotril

N,N,N-trimethylethanol-ammonium

N,N,N-Trimethylethanolammonium

N,N,N-Trimethylethanol-ammonium

Neocolina

N-trimethylethanolamine

N-Trimethylethanolamine

O-Sulfate, choline

Paresan

trimethylethanolamine

Trimethylethanolamine

Vidine

Vitamin J

Hypolipidemic Agents

Phase 3

Gastrointestinal Agents

Phase 3

Nootropic Agents

Phase 3

Antimetabolites

Phase 3

Lipid Regulating Agents

Phase 3

Interventional clinical trials:

#	Name	Status	NCT ID	Phase	Drugs
1	4-aminopyridine Treatment for Nerve Injury Resulting From Radical Retro-Pubic Prostatectomy	Not yet recruiting	NCT03701581	Phase 4	4-Aminopyridine
2	Expanded Access to 11C Choline PET/CT and 11C Choline PET/MR for Staging of Recurrent Prostate Cancer With Comparison Study of CT and MR Modalities	Completed	NCT02260817	Phase 3	11C-choline Injection
3	A Collagen-Fibrin Patch (Tachosil®) for the Prevention of Symptomatic Lymphoceles After Pelvic Lymphadenectomy in Women With Gynecologic Malignancies: a Randomized Clinical Trial	Completed	NCT01470677	Phase 3	Tachosil fibrin patch
4	A Multi-centre, Two-stage, Open Label Phase II Study to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Advanced Melanoma.	Completed	NCT00432107	Phase 2	APO866
5	A Multicenter Open Label Phase II Study of to Assess the Efficacy and Safety of APO866 in the Treatment of Patients With Refractory or Relapsed Cutaneous T-cell Lymphoma	Completed	NCT00431912	Phase 2	APO866

Search NIH Clinical Center for Prostate Cancer, Hereditary, 4

Sources

Genetic Tests for Prostate Cancer, Hereditary, 4

Sources

Anatomical Context for Prostate Cancer, Hereditary, 4

MalaCards organs/tissues related to Prostate Cancer, Hereditary, 4:

⁴⁰

Prostate, T Cells, Lung, Breast, Testes

Sources

Publications for Prostate Cancer, Hereditary, 4

Articles related to Prostate Cancer, Hereditary, 4:

(show top 50) (show all 52)

#	Title	Authors	PMID	Year
1	Multiple newly identified loci associated with prostate cancer susceptibility. ⁵⁶	Eeles RA...Easton DF	18264097	2008
2	Identification of a prostate cancer susceptibility locus on chromosome 7q11-21 in Jewish families. ⁵⁶	Friedrichsen DM...Xu J	14769943	2004
3	Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017. ⁶¹	Saad M...Ong TA	31077523	2019
4	The Role of Stabilization-Free Microsurgical Decompression in the Surgical Treatment of Spinal Metastases. ⁶¹	Muller M...Bostelmann R	31562975	2019
5	Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma. ⁶¹	Juptner M...Lutzen U	31140181	2019
6	Characterization of the Recommendations in the Choosing Wisely Initiative. ⁶¹	Corrigan K...Kamal A	30345804	2019
7	Prostate cancer detection using quantitative T2 and T2 -weighted imaging: The effects of 5-alpha-reductase inhibitors in men on active surveillance. ⁶¹	Giganti F...Kirkham A	29135073	2018
8	Gambogic Acid Induces Cell Apoptosis and Inhibits MAPK Pathway in PTEN-/-/p53-/- Prostate Cancer Cells In Vitro and Ex Vivo. ⁶¹	Pan H...Lin HS	28578487	2018
9	The Efficacy of Transrectal Ultrasound Guided Biopsy Versus Transperineal Template Biopsy of the Prostate in Diagnosing Prostate Cancer in Men with Previous Negative Transrectal Ultrasound Guided Biopsy. ⁶¹	Nafie S...Khan M	28299763	2017
10	Risk assessment models to evaluate the necessity of prostate biopsies in North Chinese patients with 4-50 ng/mL PSA. ⁶¹	Zhao J...Lu J	28039477	2017
11	Clinical Translation of a Dual Integrin αvβ3- and Gastrin-Releasing Peptide Receptor-Targeting PET Radiotracer, 68Ga-BBN-RGD. ⁶¹	Zhang J...Chen X	27493267	2017
12	Non-Prostate-Specific Membrane Antigen-Avid Metastatic Lung Nodule From Primary Prostatic Adenocarcinoma. ⁶¹	Shetty D...Do V	27556788	2016
13	Simultaneous PET/MRI vs PET/CT in oncology. A systematic review. ⁶¹	Riola-Parada C...Carreras-Delgado JL	27424217	2016
14	[Mechanisms of castration resistance: Intratumoral hypoxia stimulates the androgen receptor expression]. ⁶¹	Lunardi P...Malavaud B	26896427	2016
15	Lung Cancer and Multiple Neoplasms: A Retrospective Analysis. ⁶¹	Romaszko A...Luks J	26987325	2016
16	Prostate cancer: 4 big questions. ⁶¹	Hodson R	26672789	2015
17	[On "2015 Guidelines for Prevention and Treatment of Osteoporosis". Osteoporosis associated with sex hormone depletion treatment]. ⁶¹	Takahashi S	26320536	2015
18	Apigenin inhibits migration and invasion via modulation of epithelial mesenchymal transition in prostate cancer. ⁶¹	Zhu Y...Xie L	25351792	2015
19	The epidemiology of cancer in Angola-results from the cancer registry of the national oncology centre of Luanda, Angola. ⁶¹	Armando A...Miguel F	25729423	2015
20	Adherence to Mediterranean diet and risk of cancer: a systematic review and meta-analysis of observational studies. ⁶¹	Schwingshackl L...Hoffmann G	24599882	2014
21	Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. ⁶¹	Lane JA...ProtecT study group	25163905	2014
22	Prostate cancer progression correlates with increased humoral immune response to a human endogenous retrovirus GAG protein. ⁶¹	Reis BS...Gnjatic S	24081977	2013
23	Genetic testing in the European Union: does economic evaluation matter? ⁶¹	Antonanzas F...Pinillos M	21598012	2012
24	Stomach metastasis in a patient with prostate cancer 4 years after the initial diagnosis: a case report and a literature review. ⁶¹	Bilici A...Selcukbiricik F	23243531	2012
25	Overdiagnosis of a typical carcinoid tumor as an adenocarcinoma of the lung: a case report and review of the literature. ⁶¹	Demirci I...Jan?en H	22269186	2012
26	Robotic-assisted minimally invasive surgery for gynecologic and urologic oncology: an evidence-based analysis. ⁶¹	Medical Advisory Secretariat	23074405	2010
27	Effects of interval between diagnosis and time of survey upon preferred information format for prostate cancer patients. ⁶¹	Sharpley CF...Christie DR	19527371	2009
28	Defining increased future risk for prostate cancer: evidence from a population based screening cohort. ⁶¹	Schroder FH...Fleshner N	19012915	2009
29	[Antioxidant power and cellular damage in prostate cancer]. ⁶¹	Lopez Laur JD...Ortiz A	18709810	2008
30	What contributes more strongly to predicting QOL during 1-year recovery from treatment for clinically localized prostate cancer: 4-weeks-post-treatment depressive symptoms or type of treatment? ⁶¹	Monahan PO...Koch M	17091363	2007
31	Inflammatory myofibroblastic tumors of the urinary tract: a clinicopathologic study of 46 cases, including a malignant example inflammatory fibrosarcoma and a subset associated with high-grade urothelial carcinoma. ⁶¹	Montgomery EA...Epstein JI	17122505	2006
32	Pleomorphic giant cell adenocarcinoma of the prostate: report of 6 cases. ⁶¹	Parwani AV...Epstein JI	17001156	2006
33	Confidence and uncertainty long after initial treatment for early prostate cancer: survivors' views of cancer control and the treatment decisions they made. ⁶¹	Clark JA...Talcott JA	16983114	2006
34	Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. ⁶¹	Kobayashi N...Aronson WJ	16899616	2006
35	Prostate tumor growth and recurrence can be modulated by the omega-6:omega-3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy. ⁶¹	Kelavkar UP...McHugh K	16611404	2006
36	Therapeutic targeting of prostate cancer. ⁶¹	Cress AE...Mohla S	15539935	2004
37	Effect of isocaloric low-fat diet on prostate cancer xenograft progression to androgen independence. ⁶¹	Ngo TH...Aronson WJ	14973081	2004
38	Ethnic differences in quality of life among early breast and prostate cancer survivors. ⁶¹	Gotay CC...Pagano I	11921326	2002
39	Changes in natural killer cell activity by external radiotherapy and/or brachytherapy. ⁶¹	Yamazaki H...Inoue T	11836608	2002
40	[Ultrasound-guided biopsy: screening of prostate cancer with a single set of 14 systematic biopsies]. ⁶¹	Perdona S...D'Armiento M	11221051	2000
41	[RT-PCR assay for detecting PSA mRNA in peripheral blood of prostate cancer patients]. ⁶¹	Okubo Y...Ito T	10086262	1999
42	Prostate cancer: 4. Screening. ⁶¹	Meyer F...Fradet Y	9834724	1998
43	Insulin-like growth factors and prostate cancer. ⁶¹	Pollak M...Zhang JC	10453282	1998
44	[Study on the quality of life in patients with prostate cancer]. ⁶¹	Du SF...Zhang HJ	9812508	1997
45	Prediction of significant cancer in men with stage T1c adenocarcinoma of the prostate. ⁶¹	Carter HB...Epstein JI	9436285	1997
46	Cancer mortality among pulp and paper workers in Poland. A cohort study. ⁶¹	Szadkowska-Stanczyk I...Szymczak W	9187043	1997
47	Combined finasteride and flutamide therapy in men with advanced prostate cancer. ⁶¹	Ornstein DK...Andriole GL	8973674	1996
48	[Screening of cancer of the prostate: study in a Spanish population]. ⁶¹	Herrero Payo JA...Berenguer Sanchez A	8929102	1996
49	Update on urology--prostate cancer. 4--Treatment of local disease. ⁶¹	Bowsher WG	8631420	1995
50	[Studies on 5-FU concentration in serum and prostate cancer tissue after oral administration of UFT]. ⁶¹	Shinoda I...Tada K	1927771	1991

Sources

Genes for Prostate Cancer, Hereditary, 4

Genes related to Prostate Cancer, Hereditary, 4 (1 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	HPC4	Prostate Cancer, Hereditary, 4	Genetic Locus	58.3	Susceptibility factor ⁵⁶ GeneCards inferred via : Gene name (show sections)

Sources

Variations for Prostate Cancer, Hereditary, 4

Sources

Expression for Prostate Cancer, Hereditary, 4

Search GEO for disease gene expression data for Prostate Cancer, Hereditary, 4.

Sources

Pathways for Prostate Cancer, Hereditary, 4

Sources

GO Terms for Prostate Cancer, Hereditary, 4

Sources

Sources for Prostate Cancer, Hereditary, 4

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MeSH

⁴⁴ MESH via Orphanet

⁴⁵ MGI

⁴⁶ miR2Disease

⁴⁷ NCBI Bookshelf

⁴⁸ NCI

⁴⁹ NCIt

⁵⁰ NDF-RT

⁵¹ NIH Clinical Center

⁵² NIH Rare Diseases

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM

⁵⁷ OMIM via Orphanet

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia

Prostate Cancer, Hereditary, 4 (HPC4)

Aliases & Classifications for Prostate Cancer, Hereditary, 4

MalaCards integrated aliases for Prostate Cancer, Hereditary, 4:

Classifications:

External Ids:

Summaries for Prostate Cancer, Hereditary, 4

Related Diseases for Prostate Cancer, Hereditary, 4

Diseases in the Prostate Cancer family:

Diseases related to Prostate Cancer, Hereditary, 4 via text searches within MalaCards or GeneCards Suite gene sharing:

Symptoms & Phenotypes for Prostate Cancer, Hereditary, 4

Clinical features from OMIM:

Drugs & Therapeutics for Prostate Cancer, Hereditary, 4

Drugs for Prostate Cancer, Hereditary, 4 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Genetic Tests for Prostate Cancer, Hereditary, 4

Anatomical Context for Prostate Cancer, Hereditary, 4

MalaCards organs/tissues related to Prostate Cancer, Hereditary, 4:

Publications for Prostate Cancer, Hereditary, 4

Articles related to Prostate Cancer, Hereditary, 4:

Genes for Prostate Cancer, Hereditary, 4

Genes related to Prostate Cancer, Hereditary, 4 (1 elite genes):

Variations for Prostate Cancer, Hereditary, 4

Expression for Prostate Cancer, Hereditary, 4

Pathways for Prostate Cancer, Hereditary, 4

GO Terms for Prostate Cancer, Hereditary, 4

Sources for Prostate Cancer, Hereditary, 4